OnkoSightTM Next-Generation Sequencing (NGS) Tumor Mutation Burden
The significance of Tumor Mutation Burden (TMB) as a critical molecular biomarker in clinical oncology is being increasingly recognized. High levels of TMB have been reported to positively predict favorable therapeutic response to immune checkpoint inhibitor agents across tumor types. High TMB levels are known to be especially prevalent among non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma, among others.
OnkoSightTM NGS tumor mutation burden assay requires a minimal sample of 10-20ng and can interrogate ~1.7MB of the genome, thus increasing accuracy.
• TG47-6 Tumor Mutation Burden (Non-NY)
• TG48-4 Tumor Mutation Burden (NY)
Can accept FFPE blocks, Cytology smear slides (Diff Quick, Papanicolau stained smears).
If no FFPE block, prefer minimum 4-5 histologic slides.
7-10 days from receipt of specimen at the lab
OnkoSight NGS Tumor Mutation Burden Sample Report